Including the settlement payment, Moderna now expects to end 2026 with between $4.5 billion and $5 billion in cash and cash ...

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

Moderna Inc. MRNA shares are up during Wednesday’s premarket session following a settlement agreement with Arbutus Biopharma ...

Moderna (MRNA) stock jumped 8.7% after announcing a $950M patent settlement with Arbutus and Genevant, the largest pharma patent deal ever recorded.

The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind. The FDA had previously rejected Moderna's application, refusing even to ...

Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed to pay up to $2.25 billion to two other biotechnology companies to [settle patent litigation]( ...

Moderna’s stock climbed in after-hours trading while shares of Arbutus fell.

Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct ...

CHONGQING, CHINA - FEBRUARY 3: In this photo illustration, a smartphone displays the logo of Moderna, Inc. (NASDAQ: MRNA), a U.S.-based biotechnology company specializing in messenger RNA (mRNA) ...

Moderna (MRNA) stock has shed roughly 90% of its value since its 2021 peak. When I wrote about the Moderna stock setup last week, shares sat around $50. Today they’ve nudged back to about $53 — but ...

Moderna has faced good and bad times in recent years. Most recently, the FDA refused to review Moderna’s flu candidate -- then reversed course. These 10 stocks could mint the next wave of millionaires ...